Can Absci’s (ABSI) Improving Loss Per Share Reshape Confidence in Its Turnaround Strategy?

• Absci Corporation reported its third quarter and nine-month earnings for 2025, posting net losses of US$28.71 million and US$85.62 million, respectively, but showing a narrowing loss per share from continuing operations compared to the previous year.
• This suggests that while losses remain, the company managed to slightly improve its per-share performance year over year.
• We'll explore how Absci's improvement in loss per share shapes its overall investment story amid ongoing financial challenges.

We've found 15 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

What Is Absci's Investment Narrative?

To be on board with Absci as a shareholder, you really have to have conviction in its AI-driven drug discovery platform and the potential payoff from ongoing clinical programs, particularly ABS-201, which is moving toward trial initiation. The latest earnings results confirm that, while losses are substantial, the loss per share is narrowing a bit year over year, hinting at a degree of cost discipline. However, this improvement hasn’t had a marked effect on the stock’s recent performance, as shares have seen a sharp decline over the last month. Near-term catalysts, like the start of the ABS-201 trial and any partnership news, remain unchanged in their importance. Risks, especially Absci’s limited cash runway, continuing share dilution and lack of profitability, aren't really addressed by this quarter’s results, so the business case here still relies largely on pipeline progress and execution. But the company’s tight cash position is something investors shouldn’t overlook.

Insights from our recent valuation report point to the potential overvaluation of Absci shares in the market.

Exploring Other Perspectives

Within the Simply Wall St Community, eight retail investors offered fair value estimates for Absci ranging from as low as US$0.20 up to US$9.50 per share. These wide opinions reflect just how differently people see Absci’s future, especially with ongoing cash burn and trial milestones making performance hard to predict. If you’re weighing up Absci, exploring these varied viewpoints can highlight risks and opportunities you might have missed.

Explore 8 other fair value estimates on Absci - why the stock might be worth less than half the current price!

Build Your Own Absci Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Absci research is our analysis highlighting 1 key reward and 5 important warning signs that could impact your investment decision.
• Our free Absci research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Absci's overall financial health at a glance.

Seeking Other Investments?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Find companies with promising cash flow potential yet trading below their fair value.
• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• These 15 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com